相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
R. Scott Wright et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms
Afsane Bahrami et al.
AGEING RESEARCH REVIEWS (2020)
The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review
Hossein Bagheri et al.
BIOFACTORS (2020)
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition
Arturo Cesaro et al.
BIOFACTORS (2020)
PCSK9 is a promising prognostic marker in patients with advanced NSCLC
Aldo Bonaventura et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer
James Yarmolinsky et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis
Saadiya Zia et al.
MEDICAL HYPOTHESES (2020)
Contribution of the Low-Density Lipoprotein Receptor Family to Breast Cancer Progression
Oceane Campion et al.
FRONTIERS IN ONCOLOGY (2020)
Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor
Khaldoun S. Abdelwahed et al.
PHARMACOLOGICAL RESEARCH (2020)
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
Silvano Fasolato et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Xinjian Liu et al.
NATURE (2020)
Effects of immunisation against PCSK9 in mice bearing melanoma
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2020)
Statins and the COVID-19 main protease: in silico evidence on direct interaction
Zeljko Reiner et al.
ARCHIVES OF MEDICAL SCIENCE (2020)
Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
Amir Abbas Momtazi-Borojeni et al.
ATHEROSCLEROSIS (2019)
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study
Aldo Bonaventura et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
PCSK9 and inflammation: a review of experimental and clinical evidence
Amir Abbas Momtazi-Borojeni et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
被撤回的出版物: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis (Retracted article. See vol. 21, 2023)
Amir Abbas Momtazi-Borojeni et al.
BMC MEDICINE (2019)
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Effects of immunization against PCSK9 in an experimental model of breast cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity
Zhubing Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Massimo R. Mannarino et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Cholesterol negatively regulates IL-9-producing CD8+ T cell differentiation and antitumor activity
Xingzhe Ma et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A
Zhubing Li et al.
JOURNAL OF GENERAL VIROLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
A Mendelian randomization study of the effects of blood lipids on breast cancer risk
Christoph Nowake et al.
NATURE COMMUNICATIONS (2018)
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
Dipti Athavale et al.
CANCER & METABOLISM (2018)
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Gerald Fitzgerald et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2018)
A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition
Jian'an Bai et al.
ONCOTARGET (2017)
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
Christine Landlinger et al.
EUROPEAN HEART JOURNAL (2017)
LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies
Barbara Rizzacasa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism
Matteo Pirro et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
PCSK9 at the crossroad of cholesterol metabolism and immune function during infections
Francesco Paciullo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells
Mingyan He et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors
Sophia Morel et al.
JOURNAL OF LIPID RESEARCH (2017)
Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia
E. J. Gallagher et al.
ONCOGENE (2017)
Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance
J. Vaquero et al.
ONCOGENE (2017)
Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells
Si-Shun Gan et al.
ONCOTARGETS AND THERAPY (2017)
PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
Xiaohui Xu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Membrane cholesterol access into a G-protein-coupled receptor
Ramon Guixa-Gonzalez et al.
NATURE COMMUNICATIONS (2017)
Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9
Mingyan He et al.
ONCOTARGET (2017)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Amand F. Schmidt et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9
Anastasia Hyrina et al.
EBIOMEDICINE (2017)
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
Luca Liberale et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
Maria Pia Adorni et al.
ATHEROSCLEROSIS (2017)
Exploring association between statin use and breast cancer risk: an updated meta-analysis
Md. Mohaimenul Islam et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2017)
Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way
Klaus-Dieter Schlueter et al.
BASIC RESEARCH IN CARDIOLOGY (2017)
Cholesterol uptake and regulation in high-grade and lethal prostate cancers
Konrad H. Stopsack et al.
CARCINOGENESIS (2017)
Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer
Qiuping Liu et al.
CANCER LETTERS (2017)
Chemotherapy for hepatocellular carcinoma: The present and the future
Marco Le Grazie et al.
WORLD JOURNAL OF HEPATOLOGY (2017)
Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)
Ting Zhou et al.
BMC CANCER (2017)
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth
Siyuan Xia et al.
CELL METABOLISM (2017)
A link between hypercholesterolemia and chronic lymphocytic leukemia
Signy Chow et al.
LEUKEMIA & LYMPHOMA (2016)
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer
Jessica E. Stine et al.
ONCOTARGET (2016)
Lipid biomarkers and long-term risk of cancer in the Women's Health Study
Paulette D. Chandler et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2016)
Blood Lipid Concentrations and Colorectal Adenomas: A Systematic Review and Meta-Analysis of Colonoscopy Studies in Asia, 2000-2014
Michael N. Passarelli et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Yajnavalka Banerjee et al.
ATHEROSCLEROSIS (2016)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers
Genaro R. Villa et al.
CANCER CELL (2016)
The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice
Claudia Lanterna et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Cellular Cholesterol Directly Activates Smoothened in Hedgehog Signaling
Pengxiang Huang et al.
CELL (2016)
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study
Wendy E. Hague et al.
CIRCULATION (2016)
Possible involvement of PCSK9 overproduction in hyperlipoproteinemia associated with hepatocellular carcinoma: A case report
Shuichi Nagashima et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Statins Use and Risk of Breast Cancer Recurrence and Death: A Systematic Review and Meta-Analysis of Observational Studies
Marjan Mansourian et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2016)
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Wei Yang et al.
NATURE (2016)
The impact of statin therapy on plasma levels of von Willebrand factor antigen Systematic review and meta-analysis of randomised placebo-controlled trials
Amirhossein Sahebkar et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
Nicola Ferri et al.
TRANSLATIONAL RESEARCH (2016)
High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer
Siker Kimbung et al.
ONCOTARGET (2016)
Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer
Jia Li et al.
SCIENTIFIC REPORTS (2016)
Tumor-Induced Hyperlipidemia Contributes to Tumor Growth
Jianfeng Huang et al.
CELL REPORTS (2016)
Cholesterol activates the G-protein coupled receptor Smoothened to promote Hedgehog signaling
Giovanni Luchetti et al.
eLife (2016)
Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
Aarti Ramanathan et al.
PLOS ONE (2016)
Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins
Yosuke Furuya et al.
PROSTATE INTERNATIONAL (2016)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia
Nicola Ferri et al.
ENDOCRINE (2016)
PCSK9 inhibitors - clinical applications
Robert Schmidli
AUSTRALIAN PRESCRIBER (2016)
PCSK9 inhibitors - mechanisms of action
Michael M. Page et al.
AUSTRALIAN PRESCRIBER (2016)
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia A Systematic Review and Meta-analysis
Eliano Pio Navarese et al.
ANNALS OF INTERNAL MEDICINE (2015)
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Rainer Schulz et al.
BASIC RESEARCH IN CARDIOLOGY (2015)
Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study
David de Gonzalo-Calvo et al.
BMC CANCER (2015)
Decreased PCSK9 expression in human hepatocellular carcinoma
Mamatha Bhat et al.
BMC GASTROENTEROLOGY (2015)
Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies
Mathilde Touvier et al.
BRITISH JOURNAL OF NUTRITION (2015)
Plasma lipid levels and colorectal adenoma risk
John-Anthony Coppola et al.
CANCER CAUSES & CONTROL (2015)
Cross-talk between LOX-1 and PCSK9 in vascular tissues
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2015)
Metabolites Produced by the Endophytic Fungus Aspergillus fumigatus from the Stem of Erythrophloeum fordii Oliv.
Yu-Sheng Shi et al.
MOLECULES (2015)
In vivo genome editing using Staphylococcus aureus Cas9
F. Ann Ran et al.
NATURE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Serum Lipids and Breast Cancer Risk: A Meta-Analysis of Prospective Cohort Studies
Haibo Ni et al.
PLOS ONE (2015)
MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer
Ri Cui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
Fabienne Guillaumond et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The association between serum lipids and colorectal neoplasm: a systemic review and meta-analysis
Yun Tian et al.
PUBLIC HEALTH NUTRITION (2015)
A cholesterol-lowering VLP vaccine that targets PCSK9
Erin Crossey et al.
VACCINE (2015)
MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7
Ri Cui et al.
ONCOTARGET (2015)
Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer
Long Jiang et al.
ONCOTARGET (2015)
MicroRNA-224 Induces G1/S Checkpoint Release in Liver Cancer
Fangmei An et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial
Anders Green et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression
Catarina Rodrigues dos Santos et al.
BMC CANCER (2014)
Obesity, Cholesterol Metabolism, and Breast Cancer Pathogenesis
Donald P. McDonnell et al.
CANCER RESEARCH (2014)
Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness
Shuhua Yue et al.
CELL METABOLISM (2014)
Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro
Christina I. Schroeder et al.
CHEMISTRY & BIOLOGY (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Qiurong Ding et al.
CIRCULATION RESEARCH (2014)
Molecular Pathways: Sterols and Receptor Signaling in Cancer
Linara Gabitova et al.
CLINICAL CANCER RESEARCH (2014)
Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk
Mathilde His et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2014)
Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
Yingnan Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Subcutaneous Adipocytes Promote Melanoma Cell Growth by Activating the Akt Signaling Pathway ROLE OF PALMITIC ACID
Hiu Yee Kwan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Statin Use After Colorectal Cancer Diagnosis and Survival: A Population-Based Cohort Study
Chris R. Cardwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
LDL-cholesterol signaling induces breast cancer proliferation and invasion
Catarina Rodrigues dos Santos et al.
LIPIDS IN HEALTH AND DISEASE (2014)
LDL receptor knock-out mice show impaired spatial cognition with hippocampal vulnerability to apoptosis and deficits in synapses
Shao-hua Wang et al.
LIPIDS IN HEALTH AND DISEASE (2014)
Lectin-Like Oxidized LDL Receptor-1 Is an Enhancer of Tumor Angiogenesis in Human Prostate Cancer Cells
Ivan Gonzalez-Chavarria et al.
PLOS ONE (2014)
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Gergana Galabova et al.
PLOS ONE (2014)
Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland
Teemu J. Murtola et al.
PLOS ONE (2014)
Lipid levels in serum and cancerous tissues of colorectal cancer patients
Xin Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering
Tracy Mitchell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
The Association of Serum Lipids With Colorectal Adenomas
Moon Hee Yang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of ABCA1
Byron H. Lee et al.
CANCER RESEARCH (2013)
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Nabil G. Seidah
CURRENT PHARMACEUTICAL DESIGN (2013)
Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model
N. Alikhani et al.
ONCOGENE (2013)
Total Serum Cholesterol and Cancer Incidence in the Metabolic Syndrome and Cancer Project (Me-Can)
Susanne Strohmaier et al.
PLOS ONE (2013)
Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios
Ilya V. Demidyuk et al.
PLOS ONE (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
SILAC-based quantitative proteomic analysis of gastric cancer secretome
Arivusudar Marimuthu et al.
PROTEOMICS CLINICAL APPLICATIONS (2013)
Hepatitis C Virus, Cholesterol and Lipoproteins - Impact for the Viral Life Cycle and Pathogenesis of Liver Disease
Daniel J. Felmlee et al.
VIRUSES-BASEL (2013)
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Bo Zhai et al.
WORLD JOURNAL OF HEPATOLOGY (2013)
Association of colorectal adenoma with components of metabolic syndrome
Byung Chang Kim et al.
CANCER CAUSES & CONTROL (2012)
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kai Kysenius et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Control of the immune system by oxysterols and cancer development
Catia Traversari et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Cholesterol and prostate cancer
Kristine Pelton et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice
Elena Fattori et al.
JOURNAL OF LIPID RESEARCH (2012)
PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
Marie W. Lindholm et al.
MOLECULAR THERAPY (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Statin Use and Reduced Cancer-Related Mortality
Sune F. Nielsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
LDL Receptor Knock-Out Mice Are a Physiological Model Particularly Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease
Veerle Bieghs et al.
PLOS ONE (2012)
Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
Jonathan R. Emberson et al.
PLOS ONE (2012)
The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth
Teemu J. Murtola et al.
PLOS ONE (2012)
Knockdown of scavenger receptor Class B Type I reduces prostate specific antigen secretion and viability of prostate cancer cells
Alexis L. Twiddy et al.
PROSTATE (2012)
Cholesterol modulates cell signaling and protein networking by specifically interacting with PDZ domain-containing scaffold proteins
Ren Sheng et al.
NATURE COMMUNICATIONS (2012)
Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
Xiaowei Sun et al.
NEOPLASIA (2012)
Role of Cholesterol in the Development and Progression of Breast Cancer
Gemma Llaverias et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Risk of Colorectal Cancer in Self-Reported Inflammatory Bowel Disease and Modification of Risk by Statin and NSAID Use
N. Jewel Samadder et al.
CANCER (2011)
Serum total and HDL cholesterol and risk of prostate cancer
Alison M. Mondul et al.
CANCER CAUSES & CONTROL (2011)
Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
Eric J. Jacobs et al.
CANCER RESEARCH (2011)
Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification
Caryl J. Antalis et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition
Franzel J. B. van Duijnhoven et al.
GUT (2011)
Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
Fen Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Total Cholesterol and Cancer Risk in a Large Prospective Study in Korea
Cari M. Kitahara et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Low Cholesterol is Associated With Mortality From Stroke, Heart Disease, and Cancer: The Jichi Medical School Cohort Study
Naoki Nago et al.
JOURNAL OF EPIDEMIOLOGY (2011)
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
Estelle Rousselet et al.
JOURNAL OF LIPID RESEARCH (2011)
The Lipogenesis Pathway as a Cancer Target
Hanley N. Abramson
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study
Marianne Benn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway
Deliang Guo et al.
CANCER DISCOVERY (2011)
High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation
Caryl J. Antalis et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes
Thea Bismo Strom et al.
CLINICA CHIMICA ACTA (2010)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Mali Liu et al.
JOURNAL OF LIPID RESEARCH (2010)
Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies
Themistocles L. Assimes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9
Oystein L. Holla et al.
MOLECULAR GENETICS AND METABOLISM (2010)
RCeveierwamide and ceramide 1-phosphate in health and disease
Lide Arana et al.
LIPIDS IN HEALTH AND DISEASE (2010)
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
John Wojcik et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Alterations in Cholesterol Regulation Contribute to the Production of Intratumoral Androgens During Progression to Castration-Resistant Prostate Cancer in a Mouse Xenograft Model
Carlos G. Leon et al.
PROSTATE (2010)
Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol
Pamela Cruz et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2010)
Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172 210 men and women: a prospective 19-year follow-up study
A. M. Strasak et al.
ANNALS OF ONCOLOGY (2009)
PCSK9 as a therapeutic target of dyslipidemia
Nabil G. Seidah
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Hepatitis C Virus Infection and Its Clearance Alter Circulating Lipids: Implications for Long-Term Follow-Up
Kathleen E. Corey et al.
HEPATOLOGY (2009)
Serum cholesterol levels in relation to the incidence of cancer: The JPHC study cohorts
Hiroyasu Iso et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer
Toshiro Migita et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Primary prevention of cardiovascular disease with statins: cautionary notes
M. R. Goldstein et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2009)
Suppression of Annexin A11 in Ovarian Cancer: Implications in Chemoresistance
Jin Song et al.
NEOPLASIA (2009)
Statins and cancer risk
Igor Karp et al.
AMERICAN JOURNAL OF MEDICINE (2008)
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
LiXin Shan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells
Maria T. Accioly et al.
CANCER RESEARCH (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
The activation and physiological functions of the proprotein convertases
Nabil G. Seidah et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Association between plasma cholesterol and prostate cancer in the PSA era
Elizabeth A. Platz et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9
Trine Ranheim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Reduced expression of low-density lipoprotein receptor in hepatocellular carcinoma with paraneoplastic hypercholesterolemia
Tetsuro Sohda et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
PCSK9 function and physiology
Andrew S. Peterson et al.
JOURNAL OF LIPID RESEARCH (2008)
Sorafenib in liver cancer - Just the beginning
Lewis R. Roberts
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
Da-Wei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Sterol regulators of cholesterol homeostasis and beyond: The oxysterol hypothesis revisited and revised
Saloni Gill et al.
PROGRESS IN LIPID RESEARCH (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
LDL receptor deficiency results in decreased cell proliferation and presynaptic bouton density in the murine hippocampus
Monique Mulder et al.
NEUROSCIENCE RESEARCH (2007)
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li et al.
BIOCHEMICAL JOURNAL (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction
Hea Young Oh et al.
PROSTATE (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nasha Nassoury et al.
TRAFFIC (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Statins and the risk of lung, breast, and colorectal cancer in the elderly
Soko Setoguchi et al.
CIRCULATION (2007)
Approaches to the study of the cell secretome
Yetrib Hathout
EXPERT REVIEW OF PROTEOMICS (2007)
Increased lipogenesis in cancer cells: new players, novel targets
Johannes V. Swinnen et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2006)
The metabolic syndrome and risk of incident colorectal cancer
Rehana L. Ahmed et al.
CANCER (2006)
Statin use and breast cancer: Prospective results from the Women's Health Initiative
JA Cauley et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?
JW Heinecke
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Proprotein convertases: Master switches in the regulation of tumor growth and progression
DE Bassi et al.
MOLECULAR CARCINOGENESIS (2005)
Serum lipids and outcome of early-stage breast cancer: Results of a prospective cohort study
M Bahl et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Communicating with Hedgehogs
JE Hooper et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Characterization of a nonclathrin endocytic pathway: Membrane cargo and lipid requirements
N Naslavsky et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Cell biology - How cells handle cholesterol
K Simons et al.
SCIENCE (2000)
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
H Zhang et al.
NATURE BIOTECHNOLOGY (2000)
分享论文
